Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1 Monoclonal Antibody Durvalumab in Combination With Paclitaxel in Patients With Metastatic Triple Negative PD-L1 Positive Breast Cancer

Trial Profile

Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1 Monoclonal Antibody Durvalumab in Combination With Paclitaxel in Patients With Metastatic Triple Negative PD-L1 Positive Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Durvalumab (Primary) ; Paclitaxel (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2016 Status changed from active, no longer recruiting to recruiting.
    • 17 Oct 2016 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.
    • 17 Oct 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top